Key Summary Points {#FPar1}
==================

**Why carry out this study?**Early achievement of tight glycemic control improves microvascular outcomes in type 2 diabetes, but its benefits could be offset by increased risk of hypoglycemia, particularly with regimens that include sulfonylureas or insulin.We explored whether initial treatment with the dipeptidyl peptidase-4 inhibitor linagliptin combined with metformin could elicit tight glycemic control (HbA1c ≤ 6.5%) without increasing hypoglycemia.**What was learned from this study?**The linagliptin/metformin combination more than doubled the odds ratio of achieving HbA1c ≤ 6.5% after 24 weeks of treatment compared to metformin alone, with a similar incidence of hypoglycemia.Early combination of linagliptin and metformin may improve type 2 diabetes treatment compared with metformin alone.

Introduction {#Sec1}
============

Over the past two decades, many new glucose-lowering medications have been introduced for the treatment of type 2 diabetes (T2D) \[[@CR1]\]. Despite this growing number of therapeutic options, however, glycemic management of T2D patients remains far from optimal. Although most major guidelines in the USA, Europe and Asia recommend setting a HbA1c target of \< 7% \[[@CR2]--[@CR5]\], a substantial proportion of patients with T2D do not achieve this level of glycemic control \[[@CR6]--[@CR10]\].

Tight glycemic control can bring long-term microvascular and possible macrovascular benefits, but it also may increase hypoglycemia, especially when classical glucose-lowering medications with high risk for hypoglycemia (insulin, sulfonylureas) are used for intensive therapy \[[@CR11]--[@CR14]\]. However, it is possible that the risk--benefit ratio of this strategy could be more favorable with the use of modern oral antidiabetic drugs (OADs), such as dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose co-transporter-2 (SGLT2) inhibitors, which improve glycemic control without substantially increasing the risk of hypoglycemia \[[@CR15], [@CR16]\]. Indeed, current guidelines from the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE) suggest setting a more stringent target for glycemic control (HbA1c ≤ 6.5%) for low-risk patients as long as this can be achieved without hypoglycemia or other iatrogenic adverse effects \[[@CR17], [@CR18]\]. Such patients include those who have had T2D for only a short period of time, those without comorbidities, such as cardiovascular disease, and/or those with long life expectancy. Notably, the latest consensus report from the ADA and the European Association for the Study of Diabetes (EASD) recommends that patients with indicators of high cardiovascular risk, established cardiovascular disease, heart failure or chronic kidney disease receive second-line therapy (added to metformin) with a medication with proven cardiovascular benefit, such as an SGLT2 inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist \[[@CR19]\]. For others, the ADA/EASD report suggests a DPP-4 inhibitor as an option to add to metformin, particularly where there is a compelling need to avoid hypoglycemia \[[@CR19]\].

Several clinical trials have demonstrated that early combination therapy using metformin with a modern OAD can significantly increase the number of patients achieving HbA1c \< 7.0% compared to the respective monotherapies, without increasing the incidence of hypoglycemia \[[@CR20]--[@CR23]\]. However, although most of these studies recruited early-stage T2D patients, they did not investigate the more stringent glycemic control target of HbA1c ≤ 6.5%. One of these trials evaluated the DPP-4 inhibitor linagliptin \[[@CR23]\]. We have conducted a post hoc pooled analysis of this study and of a similar randomized clinical trial of linagliptin \[[@CR24]\] to explore the hypothesis that early combination therapy of linagliptin plus metformin would help a greater proportion of T2D patients achieve HbA1c ≤ 6.5% than would metformin monotherapy, without increasing hypoglycemia.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a post hoc pooled analysis of two multi-center, phase III, double-blind, randomized clinical trials designed to investigate the glycemic efficacy and tolerability of the initial combination of linagliptin and metformin (NCT00798161: *n* = 791 \[[@CR24]\]; NCT01708902: *n* = 733 \[[@CR23]\]). In these trials, patients were aged 18--80 years at screening with HbA1c of 7.5 to \< 11.0% (for patients without any prior treatment in both studies) or of 7.0 to \< 10.5% (for patients who had previously been treated with one OAD in trial NCT00798161). Patients who had received glucose-lowering medication before screening went through a 4-week drug washout period before initiating study treatment. Patients were randomized to receive 24 weeks of treatment with either linagliptin 2.5 mg/metformin 500 mg twice daily (bid), or linagliptin 2.5 mg/metformin 1000 mg bid or the component monotherapies (metformin 500 mg bid, metformin 1000 mg bid, linagliptin 5 mg once daily); the NCT00798161 trial also had an additional placebo arm. Glycemic rescue therapy with sulfonylureas, thiazolidinediones or insulin was permitted between the start of treatment and week 12 for patients with a glucose level \> 240 mg/dL after an overnight fast or a randomly determined glucose level \> 400 mg/dL, and between weeks 12 and 24 for those with a glucose level \> 200 mg/dL after an overnight fast or a randomly determined glucose level \> 400 mg/dL. The primary endpoint in both trials was the change in HbA1c from baseline to 24 weeks of treatment. For the study reported here, we pooled and analyzed individual patient data from the following four treatment arms from both trials: linagliptin 2.5 mg/metformin 500 mg bid, linagliptin 2.5 mg/metformin 1000 mg bid, metformin 500 mg bid, metformin 1000 mg bid.

The trials were approved by the independent ethics committees or institutional review boards of each participating center and were conducted in accordance with the ethical principles of the Declaration of Helsinki (1996) and in compliance with Good Clinical Practice guidelines as defined by the International Conference on Harmonization. All patients gave written, informed consent before participation.

Assessments {#Sec4}
-----------

The homogeneity of the study design of these two clinical trials facilitated pooling and analysis of data from the studies. In this pooled analysis, the main outcome of interest was the proportion of patients who met the glycemic control target of HbA1c ≤ 6.5% at week 24. We also analyzed the proportion of patients achieving HbA1c \< 7.0% at week 24. For these outcomes, we also evaluated patient subgroups based on baseline HbA1c categories (\< 7.5%, ≥  7.5 to ≤ 9.0% or \> 9.0%). Additionally, we performed a sensitivity analysis to examine whether achievement of HbA1c ≤ 6.5% or \< 7.0% differed for patients without prior glucose-lowering treatment. Other efficacy outcomes included change from baseline to week 24 in HbA1c, fasting plasma glucose and body weight (baseline HbA1c was defined as the last available HbA1c measurement prior to the start of randomized study treatment, excluding values taken before washout). We evaluated treatment tolerability by analyzing the incidence of reported adverse events, including hypoglycemia and gastrointestinal adverse events. We classified adverse events using the Medical Dictionary for Regulatory Activities (MedDRA) version 17.0 (<https://www.meddra.org/>). Hypoglycemia was defined as a plasma glucose concentration ≤ 70 mg/dL; severe hypoglycemia was defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions, without necessarily having an accompanying plasma glucose measurement. Gastrointestinal adverse events were defined as any individual event (preferred term) in the MedDRA system organ class of gastrointestinal disorders.

Statistical Analysis {#Sec5}
--------------------

We evaluated efficacy parameters using data for the full-analysis set, which consisted of all randomized patients who received at least one dose of study drug, had a baseline HbA1c measurement and had at least one HbA1c measurement during treatment. Achievement of HbA1c targets (≤ 6.5%, \< 7.0%) was analyzed using a multivariate logistic regression model that included baseline HbA1c as a linear covariate and study and treatment as fixed factors. For this model, patients receiving glycemic rescue therapy were considered to have failed to achieve the target, while the HbA1c value for patients without glycemic rescue therapy was either derived from the measured value or, if missing, was imputed using the approach of non-completers considered to be failures. Differences between treatment groups in changes from baseline in HbA1c and fasting plasma glucose were evaluated by analysis of covariance using the last observation carried forward approach to impute missing data as well as values obtained after the initiation of glycemic rescue medication, and using the observed cases approach to analyze the change from baseline in body weight. Adverse events were summarized descriptively for the treated set, defined as all patients who were treated with at least one dose of study drug.

Results {#Sec6}
=======

Patient Characteristics {#Sec7}
-----------------------

A total of 1160 patients were included in the pooled analysis. Their clinical and demographic characteristics at baseline were well balanced across treatment groups (Table [1](#Tab1){ref-type="table"}). Mean HbA1c was approximately 8.7%, more than half of patients had had T2D for ≤ 1 year and almost three-quarters had not been previously treated with a glucose-lowering drug. Fewer than 10% of patients had diabetic microvascular complications at baseline.Table 1Baseline characteristics of patients in treated set and full-analysis setPatient characteristics at baselineTreatment armMET 500 mg bidLINA/MET 500 mg bidMET 1000 mg bidLINA/MET 1000 mg bidTreated set, *N*^a^289290291290 Male, *n* (%)173 (59.9)165 (56.9)169 (58.1)164 (56.6) Age, years, mean (SD)52.5 (10.0)53.5 (10.9)53.3 (10.7)53.5 (10.4) Age, years, *n* (%)  ≤ 50119 (41.2)119 (41.0)113 (38.8)104 (35.9)   51--64130 (45.0)127 (43.8)133 (45.7)142 (49.0)   65--7439 (13.5)36 (12.4)42 (14.4)41 (14.1)   ≥ 751 (0.3)8 (2.8)3 (1.0)3 (1.0) Race, *n* (%)  White93 (32.2)103 (35.5)95 (32.6)94 (32.4)  Black0 (0.0)2 (0.7)2 (0.7)1 (0.3)  Asian196 (67.8)185 (63.8)194 (66.7)195 (67.2) Weight, kg, mean (SD)74.50 (15.96)75.73 (16.60)75.52 (16.32)73.56 (14.40) BMI, kg/m^2^, mean (SD)27.34 (4.42)27.81 (4.88)27.83 (4.75)27.26 (4.46) BMI, kg/m^2^, *n* (%)  \< 2591 (31.5)87 (30.0)92 (31.6)97 (33.4)  25--30131 (45.3)120 (41.4)117 (40.2)124 (42.8)  ≥ 3067 (23.2)83 (28.6)82 (28.2)69 (23.8) Comorbidities, *n* (%)  Hypertension128 (44.3)132 (45.5)131 (45.0)119 (41.0)  Coronary artery disease15 (5.2)26 (9.0)20 (6.9)12 (4.1)  Dyslipidemia52 (18.0)47 (16.2)39 (13.4)42 (14.5) Complications, *n* (%)  Diabetic nephropathy11 (3.8)15 (5.2)8 (2.7)10 (3.4)  Diabetic retinopathy8 (2.8)6 (2.1)5 (1.7)8 (2.8)Full-analysis set, *N*^b^285279271281 Diabetes duration, years, *n* (%)  ≤ 1176 (61.8)173 (62.0)153 (56.5)166 (59.1)  \> 1--567 (23.5)61 (21.9)83 (30.6)70 (24.9)  \> 542 (14.7)45 (16.1)35 (12.9)45 (16.0) Antidiabetes drugs at enrollment, *n* (%)  None213 (74.7)207 (74.2)200 (73.8)206 (73.3)  Metformin only50 (17.5)49 (17.6)53 (19.6)52 (18.5)  Sulfonylurea only19 (6.7)22 (7.9)18 (6.6)23 (8.2)  Alpha-glucosidase inhibitor only1 (0.4)0 (0.0)0 (0.0)0 (0.0)  Glinide only1 (0.4)1 (0.4)0 (0.0)0 (0.0)  Metformin and sulfonylurea1 (0.4)0 (0.0)0 (0.0)0 (0.0) HbA1c, %, mean (SD)8.68 (0.98)8.68 (0.94)8.57 (0.93)8.71 (1.02) HbA1c, %, *n*  \< 7.518202626  7.5--9.0171161163151  ≥ 9.0969882104 Fasting plasma glucose, mg/dL, mean (SD)182.5 (46.3)182.7 (52.9)181.2 (47.3)181.8 (46.7)*bid* Twice daily, *BMI* body-mass index, *HbA1c* glycated hemoglobin A1c, *LINA* linagliptin, *MET* metformin, *SD* standard deviation^a^*N* = 1160. The treated set included all patients who were treated with at least one dose of study drug^b^*N* = 1116. The full-analysis set included all patients who were randomized and treated with at least one dose of study drug, had a baseline HbA1c measurement and at least one HbA1c measurement during treatment

Efficacy {#Sec8}
--------

### Percentage of Patients Who Achieved HbA1c ≤ 6.5% or \< 7.0% {#Sec9}

The proportion of patients achieving HbA1c ≤ 6.5% at 24 weeks was significantly higher with combination therapy than with metformin alone (linagliptin/metformin 500 mg bid vs. metformin 500 mg bid: 40.1 vs. 22.9%, odds ratio \[OR\] 2.84, 95% confidence interval \[CI\] 1.87--4.32, *P* \< 0.0001; linagliptin/metformin 1000 mg bid vs. metformin 1000 mg bid: 49.5 vs. 35.4%, OR 2.28, 95% CI 1.54--3.40, *P* \< 0.0001) (Table [2](#Tab2){ref-type="table"}).Table 2Patients achieving glycated hemoglobin of ≤ 6.5% or \< 7.0% at week 24 (full-analysis set, non-completers considered to be failures)Patients who achieved HbA1c ≤ 6.5% or \< 7.0%^a^MET 500 mg bidLINA/MET 500 mg bidOdds ratio (95% CI)^b^*P*valueMET 1000 mg bidLINA/MET 1000 mg bidOdds ratio (95% CI)*P*valueHbA1c ≤ 6.5%, all patients65/284 (22.9) \[18.1--28.2\]112/279 (40.1) \[34.3--46.2\]2.84 (1.87--4.32) \< 0.000196/271 (35.4) \[29.7--41.4\]139/281 (49.5) \[43.5--55.5\]2.28 (1.54--3.40) \< 0.0001 Baseline HbA1c \< 7.5%11/17 (64.7) \[38.3--85.8\]15/20 (75.0) \[50.9--91.3\]1.43 (0.27--7.72)0.674715/26 (57.7) \[36.9--76.6\]22/26 (84.6) \[65.1--95.6\]9.98 (2.04--48.72)0.0045 Baseline HbA1c ≥ 7.5% to ≤ 9.0%43/171 (25.1) \[18.8--32.3\]66/161 (41.0) \[33.3--49.0\]2.54 (1.52--4.27)0.000460/163 (36.8) \[29.4--44.7\]80/151 (53.0) \[44.7--61.1\]2.10 (1.27--3.48)0.0040 Baseline HbA1c \> 9.0%11/96 (11.5) \[5.9--19.6\]31/98 (31.6) \[22.6--41.8\]4.03 (1.77--9.14)0.000921/82 (25.6) \[16.6--36.4\]37/104 (35.6) \[26.4--45.6\]1.81 (0.88--3.70)0.1056 Treatment-naïve patients64/213 (30.0) \[24.0--36.7\]111/207 (53.6) \[46.6--60.6\]3.17 (2.05--4.91) \< 0.000191/200 (45.5) \[38.5--52.7\]125/206 (60.7) \[53.7--67.4\]2.10 (1.36--3.23)0.0007HbA1c \< 7.0%, all patients98/284 (34.5) \[29.0--40.4\]142/276 (51.4) \[45.4--57.5\]2.45 (1.66--3.60) \< 0.0001131/266 (49.2) \[43.1--55.4\]182/278 (65.5) \[59.6--71.0\]2.47 (1.67--3.65) \< 0.0001 Baseline HbA1c \< 7.5%15/17 (88.2) \[63.6--98.5\]15/17 (88.2) \[63.6--98.5\]0.85 (0.09--7.78)0.887116/21 (76.2) \[52.8--91.8\]22/23 (95.7) \[78.1--99.9\]9.50 (0.93--96.7)0.0572 Baseline HbA1c ≥ 7.5% to  ≤ 9.0%65/171 (38.0) \[30.7--45.7\]85/161 (52.8) \[44.8--60.7\]2.17 (1.33--3.52)0.001886/163 (52.8) \[44.8--60.6\]107/151 (70.9) \[62.9--78.0\]2.40 (1.44--4.00)0.0008 Baseline HbA1c \> 9.0%18/96 (18.8) \[11.5--28.0\]42/98 (42.9) \[32.9--53.3\]3.50 (1.75--7.01)0.000429/82 (35.4) \[25.1--46.7\]53/104 (51.0) \[41.0--60.9\]2.20 (1.15--4.20)0.0174 Treatment-naïve patients94/213 (44.1) \[37.4--51.1\]131/204 (64.2) \[57.2--70.8\]2.60 (1.70--3.98) \< 0.0001118/195 (60.5) \[53.3--67.4\]152/203 (74.9) \[68.3--80.7\]2.15 (1.36--3.40)0.0011The full-analysis set included all patients (*N* = 1116) who were randomized and treated with at least one dose of study drug, had a baseline HbA1c measurement and had at least one HbA1c measurement during treatment*CI* Confidence interval^a^Values for each treatment arm are presented as the ratio of patients *n*/*N*, where*n* = number of patients with HbA1c below the threshold (6.5 or 7.0%), and *N* = number of analyzed patients within treatment group, with the percentage given in parenthesis and the 95% CI given in square brackets^b^Logistic regression includes study, treatment and continuous baseline HbA1c (exact Clopper--Pearson CI)

Among patients with baseline HbA1c ≥ 7.5% to \< 9.0%, the percentage achieving HbA1c  ≤ 6.5% was significantly higher with the combination treatment than with monotherapy (500 mg metformin: 41.0 vs. 25.1%, OR 2.54, 95% CI 1.52--4.27; 1000 mg metformin: 53.0 vs. 36.8%, OR 2.10, 95% CI 1.27--3.48). The percentage of patients achieving HbA1c ≤ 6.5% was also greater with combination treatment than monotherapy among those with baseline HbA1c \< 7.5% or ≥ 9.0%, albeit the increases were not always significant (Table [2](#Tab2){ref-type="table"}).

The sensitivity analysis of patients without previous glucose-lowering treatment was consistent with the above findings from the overall population. Early treatment with initial combination of linagliptin and metformin resulted in a higher percentage of patients achieving HbA1c ≤ 6.5% than metformin alone (500 mg metformin: 53.6 vs. 30.0%, OR 3.17, 95% CI 2.05--4.91; 1000 mg metformin: 60.7 vs. 45.5%, OR 2.10, 95% CI 1.36--3.23) (Table [2](#Tab2){ref-type="table"}).

A similar treatment effect for the initial combination of linagliptin/metformin compared with metformin monotherapy was observed for achievement of HbA1c \< 7.0% (Table [2](#Tab2){ref-type="table"}).

### Change from Baseline in HbA1c, Fasting Plasma Glucose and Body Weight {#Sec10}

Significantly greater reductions in HbA1c from baseline were observed with combination therapy than with metformin alone: adjusted mean differences were − 0.53% with linagliptin/metformin 500 mg bid compared with metformin 500 mg bid, and − 0.36% with linagliptin/metformin 1000 mg bid compared with metformin 1000 mg bid (Table [3](#Tab3){ref-type="table"}). The additive effect of linagliptin also resulted in significant reductions in fasting plasma glucose relative to metformin monotherapy (Table [3](#Tab3){ref-type="table"}). Change from baseline in body weight at 24 weeks was minimal in all treatment groups (ranging from − 0.87 kg to − 0.20 kg), with no significant differences between the combination and monotherapy groups.Table 3Change from baseline at week 24 in glycated hemoglobin, body weight and fasting plasma glucose (full-analysis set)Parameters^a^MET 500 mg bid (*N* = 285)LINA/MET 500 mg bid (*N* = 279)Adjusted mean difference (95% CI)^b^*P*valueMET 1000 mg bid (*N* = 271)LINA/MET 1000 mg bid (*N* = 281)Adjusted mean difference (95% CI)^b^*P*valueHbA1c, %-- 1.14 (0.06)-- 1.67 (0.06)-- 0.53 (-- 0.69, -- 0.37) \< 0.0001-- 1.57 (0.06)-- 1.93 (0.06)-- 0.36 (-- 0.52, -- 0.20) \< 0.0001Fasting plasma glucose, mg/dL^c^-- 22.50 (2.04)-- 35.67 (2.05)-- 13.17 (--18.84, -- 7.50) \< 0.0001 --36.81 (2.10)-- 47.93 (2.05)-- 11.12 (-- 16.88, -- 5.36)0.0002Weight, kg^d^-- 0.63 (0.18)-- 0.20 (0.18)0.43 (-- 0.06, 0.92)0.0858-- 0.87 (0.18)-- 0.76 (0.18)0.12 (-- 0.37, 0.61)0.6407The full-analysis set included all patients (*N* = 1116) who were randomized and treated with at least one dose of study drug, had a baseline HbA1c measurement and at least one HbA1c measurement during treatment^a^Parameters for each treatment are presented as the adjusted mean change from baseline, with the standard error given in parenthesis^b^Analysis of covariance model includes study, treatment, continuous baseline HbA1c and the respective continuous baseline fasting plasma glucose or weight^c^Number of analyzed patients: MET 500 mg bid: *N* = 280; LINA/MET 500 mg bid: *N* = 277; MET 1000 mg bid: *N* = 265; LINA/MET 1000 mg bid: *N* = 276^d^Number of analyzed patients: MET 500 mg bid: *N* = 254; LINA/MET 500 mg bid: *N* = 259; MET 1000 mg bid: *N* = 252; LINA/MET 1000 mg bid: *N* = 264

Safety and Tolerability {#Sec11}
-----------------------

The incidence of patients with adverse events was similar among treatment groups (Table [4](#Tab4){ref-type="table"}), and the majority of adverse events were of mild or moderate intensity. Hypoglycemia was rarely reported, occurring in \< 3% of patients overall, 2.4% of those receiving linagliptin/metformin 500 mg bid, 1.0% of those receiving metformin 500 mg bid alone, 1.0% of those receiving linagliptin/metformin 1000 mg bid and 2.4% of those receiving metformin 1000 mg bid alone. The only individual to report severe hypoglycemia was a patient receiving metformin 1000 mg bid (Table [4](#Tab4){ref-type="table"}). As expected, gastrointestinal adverse events were more common in groups receiving high-dose metformin (20.6 and 20.3% for metformin 1000 mg bid alone and linagliptin/metformin 1000 mg bid, respectively) (Table [4](#Tab4){ref-type="table"}). No cases of pancreatitis were reported.Table 4Summary of adverse events (treated set)Adverse events^a^Treatment armMET 500 mg bid (*N* = 289)LINA/MET 500 mg bid (*N* = 290)MET 1000 mg bid (*N* = 291)LINA/MET 1000 mg bid (*N* = 290)All adverse events149 (51.6)146 (50.3)159 (54.6)155 (53.4)Serious adverse events4 (1.4)3 (1.0)8 (2.7)6 (2.1)Adverse events leading to discontinuation of study drug6 (2.1)7 (2.4)15 (5.2)9 (3.1)Any hypoglycemia3 (1.0)7 (2.4)7 (2.4)3 (1.0) Severe hypoglycemia0 (0.0)0 (0.0)1 (0.3)0 (0.0)Gastrointestinal adverse events37 (12.8)46 (15.9)60 (20.6)59 (20.3)Values in table are presented as a number (of patients) with the percentage in parenthesisThe treated set included all patients (*N* = 1160) who were treated with at least one dose of study drug^a^The Medical Dictionary for Regulatory Activities version 17.0 (<https://www.meddra.org/>) was used for reporting adverse events

Discussion {#Sec12}
==========

In this pooled analysis of two randomized clinical trials, initial combination therapy with the DPP-4 inhibitor linagliptin and metformin significantly increased the percentage of patients with early T2D achieving HbA1c ≤ 6.5% after 24 weeks of treatment, compared with metformin monotherapy, without increasing the risk for hypoglycemia. This is a novel finding, as achievement of tight glycemic control (HbA1c ≤ 6.5%) was not uniformly reported for the two underlying clinical trials. These patients had a relatively short duration of diabetes and few diabetic complications and were mostly treatment naive. The addition of linagliptin to low-dose metformin (500 mg bid) almost doubled the number of patients achieving HbA1c ≤ 6.5% (from 22.9% with metformin monotherapy to 40.1% with linagliptin/metformin). The addition of linagliptin to higher-dose metformin (1000 mg bid) resulted in almost half the patients achieving this glycemic goal (35.4% with metformin 1000 mg; 49.5% with linagliptin/metformin 1000 mg). Importantly, the incidence of hypoglycemia was very low (1.0--2.4%) and comparable among treatment groups. These findings suggest that combining metformin with linagliptin in early T2D can safely improve the chances of achieving tight glycemic control.

In landmark clinical trials, intensive glucose-lowering treatment designed to achieve tight glycemic control (typically HbA1c ≤ 6.5) led to significantly lower rates of long-term microvascular complications \[[@CR11], [@CR13], [@CR14]\] and, possibly, lower risk of myocardial infarction \[[@CR12]\]. However, this strategy also substantially increased the risk of hypoglycemia when high doses of sulfonylureas were used for intensive glucose-lowering therapy, as observed in the ADVANCE \[[@CR14]\] and ACCORD \[[@CR13]\] studies. Furthermore, intensive glucose lowering was associated with an increased risk for mortality in ACCORD. Unlike ACCORD, which was conducted in patients with advanced T2D \[[@CR13]\], the previous UK Prospective Diabetes Study (UKPDS) enrolled newly diagnosed T2D patients \[[@CR11]\]. The UKPDS found that intensive glucose-lowering treatment with insulin or sulfonylureas targeting fasting plasma glucose \< 108 mg/dL improved microvascular outcomes compared with conventional treatment (diet alone, at that time) \[[@CR11]\]. Furthermore, intensive treatment appeared to have a legacy effect in which microvascular benefits were maintained and macrovascular risk reduction emerged 10 years after discontinuation of randomized interventions, with subsequent convergence of glycemic control in both groups \[[@CR12]\]. Nevertheless, the mortality results from the more recent ACCORD trial may have influenced clinical guidelines moving away from recommending tight glycemic control for all T2D patients and towards a more individualized approach.

Current guidelines from the ADA and AACE, for example, recommend individualized glycemic control targets for different patient groups \[[@CR17], [@CR18]\]. HbA1c ≤ 6.5% is suggested as a treatment target for T2D patients who have had diabetes for only a short time, who have few comorbidities and/or who have long life expectancy---provided such tight glycemic control can be achieved without hypoglycemia or other iatrogenic adverse effects \[[@CR17], [@CR18]\]. Clinical guidelines in China \[[@CR3]\], Japan \[[@CR4]\] and India \[[@CR5]\] are largely in accordance with these recommendations. Compared with classical glucose-lowering drugs used as add-on to metformin (insulin, sulfonylureas), more modern medications, such as DPP-4 inhibitors and SGLT2 inhibitors, may provide better options for tight glycemic control regimens, since they can significantly lower glucose without normally increasing the risk of hypoglycemia. Despite this, HbA1c \< 7.0% remains the goal for most T2D patients, including those who could benefit from a stricter target of ≤  6.5%.

As our study shows, combining linagliptin with metformin can safely lower blood glucose levels without causing hypoglycemia or other adverse effects, such as weight gain. These findings are consistent with those from previous studies, either in patients with inadequately controlled T2D on metformin \[[@CR25]--[@CR27]\] or in patients with newly diagnosed T2D and marked hyperglycemia \[[@CR28]\]. Furthermore, the recent CAROLINA trial found that linagliptin had long-term cardiovascular safety compared with glimepiride, a sulfonylurea, in patients with early T2D and insufficient glycemic control---most of whom were receiving metformin-based regimens at baseline---but caused substantially less hypoglycemia than this widely prescribed sulfonylurea \[[@CR29]\]. Previously, the CARMELINA outcomes trial had demonstrated the long-term cardiovascular and kidney safety profile of linagliptin compared with placebo in T2D patients with high cardiovascular and renal risk \[[@CR30]\]. Again, linagliptin did not increase the risk of hypoglycemia compared with placebo even in these high-risk patients prone to hypoglycemia \[[@CR30]\].

CAROLINA and CARMELINA are among the wave of cardiovascular outcomes trials of glucose-lowering drugs over the past decade that have influenced clinical guidelines. Based on the results of these studies, the latest joint consensus report from the ADA and EASD recommends that patients with indicators of high cardiovascular risk, established cardiovascular disease, heart failure or chronic kidney disease receive second-line treatment with a glucose-lowering drug that has proven cardiovascular benefit, such as an SGLT2 inhibitor or a GLP-1 receptor agonist \[[@CR19]\]. For others, the consensus report recommends DPP-4 inhibitors, including linagliptin, as one of the options to add to metformin when there is a compelling need to avoid hypoglycemia \[[@CR19]\].

Clinical guidelines differ in their recommendations for when to consider initial combination therapy. The ADA suggests that patients who have HbA1c ≥ 1.5% above their glycemic target at the time of diagnosis should start with combination therapy \[[@CR31]\]; this would equate in most cases to a HbA1c of ≥ 8.5% or ≥ 8.0% based on the ADA targets of HbA1c \< 7.0% for most patients and HbA1c of \< 6.5% for certain other patients \[[@CR17]\]. In contrast, the AACE guidelines suggest HbA1c ≥ 7.5% as the level at which combination therapy should be initiated \[[@CR18]\]. Results from our analysis support the AACE recommendation as, compared with monotherapy, significantly more patients receiving initial combination treatment achieved HbA1c ≤ 6.5% if they had a baseline HbA1c between 7.5 and 9.0%. However, in patients with baseline HbA1c \> 9.0%, although combination therapy numerically improved the proportion achieving HbA1c ≤ 6.5%, the majority still did not reach this target---not unexpectedly, given the high baseline level; adding another OAD or insulin to the combination therapy may be considered for such patients, as suggested by the AACE guidelines \[[@CR18]\]. The ADA treatment guidelines suggest considering the early introduction of insulin for patients with HbA1c \> 10% \[[@CR31]\]. Finally, in patients with baseline HbA1c \< 7.5% in our study, the linagliptin/metformin combination was more efficacious than metformin monotherapy for achieving HbA1c ≤ 6.5% or \< 7.0% only at the higher dose of metformin (1000 mg), but the majority of patients with baseline HbA1c \< 7.5% in all treatment groups achieved these targets. Future guidelines on initial combination therapy are also likely to be impacted by the recent 5-year VERIFY study, in which initial combination treatment with the DPP-4 inhibitor vildagliptin and metformin in newly diagnosed T2D patients with HbA1c 6.5--7.5% provided greater and more durable glycemic control than metformin monotherapy \[[@CR32]\].

There are several limitations to our pooled analysis. Firstly, its retrospective nature restricted the data available for analysis; consequently, although we included patients with a relatively short duration of diabetes, we were unable to clearly define whether any given patient was suitable for an individualized glycemic control target of HbA1c ≤ 6.5%. Secondly, due to the short duration of the underlying trials, we could not determine whether achieving a lower HbA1c target by early combination therapy results in long-term stable glycemic control; longer randomized studies would be needed to confirm the durable efficacy of the linagliptin/metformin combination. Thirdly, early combination therapy was compared with continuation of metformin monotherapy, which does not reflect the common clinical practice of sequential add-on therapy, although it is in keeping with the fact that in clinical practice, patients may experience protracted periods of poor glycemic control \[[@CR33]\]. This delayed intervention (clinical inertia) is associated with an increased risk of complications \[[@CR34]\].

Conclusions {#Sec13}
===========

Our pooled analysis suggests that the early combination therapy of linagliptin and metformin can help improve the treatment of T2D compared with metformin monotherapy, in terms of achieving tight glycemic control (HbA1c ≤ 6.5%) without increasing the risk of hypoglycemia or other adverse effects.
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